The expanding role of prophylaxis with recombinant activated factor VII

Blood Transfusion

Volumn 11, Issue 1, 2013, Pages 12-13

  Tagliaferri, Annarita ^a   Franchini, Massimo ^b  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTHROPATHY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; EDITORIAL; GLANZMANN DISEASE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; PATIENT COMPLIANCE; PROPHYLAXIS; QUALITY OF LIFE;

FACTOR VIIA; HUMANS; MALE; RECOMBINANT PROTEINS; THROMBASTHENIA;

EID: 84872260862     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2012.0061-12     Document Type: Editorial

References (15)

1. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003; 1: 1138-9.
2. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163-76.
3. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000; 7: 408-13.
4. Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027-35. (Pubitemid 40823504)
5. Leissinger CA. Prophylaxis in haemophilia patients with inhibitors. Haemophilia 2006; 12 (Suppl. 6): 67-73. (Pubitemid 44741505)
6. Fischer K, Valentino L, Ljung R, Blanchette V. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. Haemophilia 2008; 14 (Suppl. 3): 196-201. (Pubitemid 351722402)
7. Hedner U. Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors? Haemophilia 2008; 14 (Suppl. 6): 23-7.
8. Brackmann HH, Effenberger E, Hess L, et al. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000; 11 (Suppl. 1): 39-44.
9. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. J Thromb Haemost 2001; 86: 1126-7. (Pubitemid 32975849)
10. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7. (Pubitemid 40723794)
11. Morfini M, Auerswald G, Kobelt RA, et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7. (Pubitemid 47337989)
12. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13. (Pubitemid 47288949)
13. Hoots WK, Ebbesen LS, Konkle B, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-75. (Pubitemid 351638732)
14. Franchini M, Manzato F, Salvagno GL, et al. Prophylaxis in hemophilia with inhibitors: the role of recombinant FVIIa. Semin Thromb Hemost 2009; 35: 814-9.
15. Giordano P, Lassandro G, Tesse R, et al. Innovative use of recombinant activated factor VII during physical rehabilitation in an Italian child with Glanzmann's thromboasthenia. Blood Transfus 2013; 11: 143-7.